Clinical response rate and flares of hidradenitis suppurativa in the treatment with adalimumab

Hidradenitis suppurativa/acne inversa (HS) is a chronic, inflammatory, skin disease. adalimumab is the sole approved drug for the treatment of HS, but it only partially controls the symptoms.To evaluate the incidence of flares during 108 weeks of therapy and the clinical response to adalimumab.In total, 20 patients with moderate-severe HS treated with adalimumab were included to evaluate the number of flares, mean time interval between flares,...